Actively Recruiting
Comparing FET Guided by ERA Vs Standard Timing in Patients with Recurrent Implantation Failure
Led by The University of Hong Kong · Updated on 2025-03-26
734
Participants Needed
1
Research Sites
175 weeks
Total Duration
On this page
Sponsors
T
The University of Hong Kong
Lead Sponsor
T
The University of Hong Kong-Shenzhen Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The pregnancy rate of in vitro fertilisation (IVF) remains around 35% per transfer. Women who are not pregnant following several embryo transfers are regarded as having recurrent implantation failure (RIF), with one of the causes being the asynchronization of the embryo and endometrium. Endometrial receptivity analysis (ERA) may identify the window of implantation and guide the timing of embryo transfer to improve the pregnancy outcomes. However, there is no randomized controlled trial on the clinical effectiveness of ERA in women with RIF. This is a multicenter double-blind randomized controlled trial. All participants will have an endometrial biopsy for ERA in a standard hormonal treatment cycle. They will then be randomly assigned in the central laboratory into the intervention or control group in a 1:1 ratio. At the transfer cycle, participants in the intervention group will have frozen embryo transfer timed according to the results of ERA while those in the control group will have the transfer according to the standard timing. The primary outcome is the ongoing pregnancy rate at 10-12 weeks at their first frozen embryo transfer.
CONDITIONS
Official Title
Comparing FET Guided by ERA Vs Standard Timing in Patients with Recurrent Implantation Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women with recurrent implantation failure
- Women aged < 40 years
- Body mass index between 18.5 (inclusive) and 30 (exclusive) kg/m²
- At least one high quality frozen blastocyst (BB grade or above) planned for single blastocyst transfer
- Women who will provide written informed consent
You will not qualify if you...
- Women with recurrent pregnancy loss (3 or more biochemical or spontaneous miscarriages)
- Either partner with known chromosomal abnormalities including balanced translocations
- Women undergoing preimplantation genetic testing
- Women with endometrial thickness < 7 mm in the IVF cycle
- Women diagnosed with stage III-IV endometriosis or adenomyosis affecting uterine cavity morphology
- Women diagnosed with antiphospholipid syndrome
- Uterine pathologies including polyps, submucosal fibroids, intramural fibroids > 4 cm, or hydrosalpinx
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Hong Kong
Hong Kong, China
Actively Recruiting
Research Team
E
Ernest HY Ng, MD
CONTACT
C
Catherine Hung, MBBS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here